CD7ΔCART19

CD7ΔCART19 is an experimental, gene-edited chimeric antigen receptor (CAR) T-cell therapy that targets the CD19 antigen. It is characterized by the genetic deletion (knockout) of the endogenous CD7 gene, typically achieved using CRISPR/Cas9 or similar genome-editing technologies. In the field of hematologic oncology research, CD7ΔCART19 is primarily utilized as a negative control in preclinical studies evaluating CD7-targeted CAR-T therapies (such as CD7ΔCART7). Because CD19 is generally not expressed on malignant T cells, this construct allows researchers to demonstrate that the anti-leukemic activity of CD7-directed therapies is antigen-specific and not a result of the gene-editing process or non-specific T-cell activation. The deletion of CD7 in the control construct mirrors the modification used in therapeutic CD7-CARs to prevent fratricide, ensuring a comparable cellular background for experimental validation.

Other names

CD7-knockout anti-CD19 CAR-TCD-7-knockout anti-CD19 CAR-TCD 7-knockout anti-CD19 CAR-TCD7-deleted anti-CD19 CAR-TCD-7-deleted anti-CD19 CAR-TCD 7-deleted anti-CD19 CAR-TCD7-knockout CART19CD-7-knockout CART19CD 7-knockout CART19